Indrayani Biotech has postponed its partly paid-up rights issue, delaying the timeline until further notice. The offer price and rights entitlement ratio remain unchanged. Investors await a revised schedule.

Indrayani Biotech Postpones Rights Issue

The Rights Issue Committee of Indrayani Biotech Limited decided on June 22, 2026, to postpone the company's partly paid-up Rights Issue. This decision follows previous outcomes from April 09, 2026, and May 25, 2026.

Reader Takeaway: A temporary delay in capital raising; core offer terms are maintained.

What just happened

Indrayani Biotech has officially postponed its planned rights issue. The Rights Issue Committee made the decision on June 22, 2026.

Why this matters

This postponement creates uncertainty around the company's capital-raising timeline. While the core terms of the offer, including the offer price and the rights entitlement ratio, remain the same as previously approved, investors will need to wait for a new schedule.

The backstory

This is a continuation of a process that has seen prior outcomes on April 09, 2026, and May 25, 2026. The company has been working through the steps for this rights issue.

What changes now

The immediate schedule for the rights issue has been delayed. The company will announce revised opening and closing dates in future filings.

Risks to watch

The primary risk is execution uncertainty regarding the capital-raising timeline. Investors should monitor subsequent exchange filings for updates on the new dates.

Investor Takeaway

The rights issue postponement is an administrative adjustment and does not alter the fundamental terms of the offer. Investors should await the company's intimation of the new issue schedule.